RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol Feb 12, 2016
RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn’s Disease Program Feb 11, 2016
RedHill Biopharma Announces Collaboration with Germany’s Fraunhofer Institute for Oncology Drug RP101 Feb 9, 2016
Resverlogix’s Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal Jan 26, 2016
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin Dec 18, 2015
Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference Nov 10, 2015
